 |
 |

Elevated Neopterin Levels in Guillain-Barré SyndromeFurther Evidence of Immune Activation
Shalini Bansil, MD;
Francis A. Mithen, MD, PhD;
Bhim S. Singhal, MD, FRCP;
Stuart D. Cook, MD;
Christine Rohowsky-Kochan, PhD
Arch Neurol. 1992;49(12):1277-1280.
Abstract
Neopterin is a by-product of guanosine triphosphate metabolism and is produced by macrophages in response to lymphocytic activation. We have studied serum neopterin levels in patients with Guillain-Barré syndrome to obtain further evidence of immune activation in this disease. Serum neopterin levels were significantly elevated in patients with Guillain-Barré syndrome compared with patients with other peripheral neuropathies and multiple sclerosis and with healthy control subjects. Serial analysis demonstrated that as neopterin levels fell, the clinical status of the patients with Guillain-Barré syndrome improved and soluble interleukin 2 receptor levels dropped. Thus, lymphocytic and macrophage activation may play a role in the pathogenesis of Guillain-Barré syndrome.
Author Affiliations
From the Department of Neurosciences, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark (Drs Bansil, Cook, and Rohowsky-Kochan); the Department of Veterans Affairs, John Cochran Medical Center, St Louis, Mo (Dr Mithen); St Louis University, School of Medicine (Dr Mithen); the Department of Neurology, Bombay (India) Hospital (Dr Singhal); and the Neurology Service, Veterans Affairs Medical Center, East Orange, NJ (Dr Cook).
Footnotes
Accepted for publication July 20, 1992.
Reprint requests to University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Department of Neurosciences, MSB H506, 185 S Orange Ave, Newark, NJ 07103 (Dr Bansil).
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Therapeutic Apheresis in Neurology Critical Care
Natarajan and Weinstein
J Intensive Care Med 2005;20:212-225.
ABSTRACT
Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients
Cook et al.
Neurology 2001;57:1080-1084.
ABSTRACT
| FULL TEXT
|